Mitsubishi UFJ Quarterly Net Profit Falls on Higher Credit Costs
By Kosaku Narioka
Mitsubishi UFJ Financial Group reported a decline in its first-quarter net profit, partly due to higher credit costs despite greater earnings from lending and higher fees.
The Japanese financial company said Thursday that net profit declined 0.4% from a year earlier to 555.89 billion yen, equivalent to $3.71 billion, for the three months ended June. That beat the estimate of Y429.38 billion in a poll of analysts by data provider Quick.
Mitsubishi UFJ said it continues to target net profit of Y1.500 trillion for the fiscal year ending March 2025.
The financial company booked total credit costs of Y166.76 billion in its first quarter, higher than Y41.64 billion a year earlier.
Net interest income--the difference between interest earned on loans and that paid on deposits--rose to Y823.13 billion from Y584.19 billion a year ago.
Japanese government bond yields have been trending higher in recent months as the Bank of Japan unwound its unorthodox monetary-easing measures. On Wednesday, the BOJ raised its policy rate to 0.25% and said it will roughly halve the amount of its monthly government bond purchases by early 2026.
Write to Kosaku Narioka at kosaku.narioka@wsj.com
(END) Dow Jones Newswires
August 01, 2024 04:01 ET (08:01 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks